


CLINICAL TRIAL

RECOVER

Neuroophthalmology RED



This trial does use Clemastine fumarat as a remyelinating agent targeting the muscarinic receptor on oligodendrocytes around the optic nerve.

Rare Eye Disease concerned by the trial :
ION, RION, CRION, NMO-ON, MOG-ON.
Also non-rare diseases: MSON

Status of the trial : Not yet recruiting

Orphan drug recognition : N/A

Inclusion criteria : Patients with acute optic neuritis including the rare forms, inclusion within 2 weeks after onset of ION, RION, CRION, etc

Exclusion criteria : Marjor ophthalmological disease, myopia >7dpt, simultaneous bilateral ON, pregnancy, other study involvement, (please see protocol for full list)



Inclusion opening date : 01/01/2018



Inclusion closing date (previsional) : 01/01/2020

Children



Adults



Within ERN-EYE members



Principal location of the trial :

Moorfields Eye Hospital

City Road
London, EC1V 2PD
UK

[Contact details](#)



Principal investigator name :

Axel Petzold




Other investigators :

Ari Green

UCSF Sandler Neuroscience Center

675 Nelson Rising Ln
San Francisco, CA 94158
USA



Funder type : Other